AbbVie price to book ratio ABBV

Market value divided by the book value of the company's net assets, since 2013.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 105×; May 2025
10-year median: 19.2×
10-year range: 10.1× to 114×
Peer median: 8.5×

AbbVie's price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in May 2025, at 105×.

On the days it had one over the last ten years, its median was 19.2×, from 10.1× in Oct 2020 to 114× in Mar 2025.

Price to book ratio over time

median 19.2×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	105×	49.9×	114×
2024	52.1×	23.7×	58.4×
2023	22.6×	15.4×	22.6×
2022	17.9×	15.0×	20.1×
2021	17.7×	11.8×	17.7×
2020	12.4×	10.1×	12.4×
2019	n/m a value too high to mean anything
2018	43.1×	24.0×	47.3×
2017	23.1×	15.1×	25.5×
2016	15.7×	14.9×	25.1×
2015	19.9×	15.1×	81.5×
2014	23.0×	16.1×	23.9×
2013	23.4×	19.0×	25.3×

Against its peers

Companies in Drug Manufacturers - General nearest AbbVie's size, closest first, today.

Company	Price to book ratio
ABBVAbbVie	n/m
JNJJohnson & Johnson	7.5×
MRKMerck	8.5×
AMGNAmgen	20.3×
LLYEli Lilly and	35.4×
GILDGilead Sciences	16.4×
PFEPfizer	2.0×
BMYBristol-Myers Squibb	5.6×
Peer median	8.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on AbbVie

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.